Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AB2 Bio

AB2 Bio?uq=kzBhZRuG
2010 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
$20.9M LATEST DEAL AMOUNT
1 INVESTORS
Description

Drug developers for inflammation-based diseases. The company develops treatments and medicines for inflammatory and autoimmune diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Primary Office
  • EPFL Innovation Park
  • Building B, 4th Floor
  • 1015 Lausanne
  • Switzerland

+41 021 000 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore AB2 Bio’s full profile, request a free trial.

AB2 Bio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 14-Jan-2016 $20.9M 000.00 Completed Generating Revenue
2. Accelerator/Incubator 000.00 Completed Startup
1. Early Stage VC $30.3M $30.3M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

AB2 Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
EPFL Innovation Park Accelerator/Incubator 000 0000 000000 0

AB2 Bio Executive Team (4)

Name Title Board
Seat
Contact
Info
Andrew Sleight Ph.D Chief Executive Officer
Fernando Cunha Chief Financial Officer
Barthélemy Helg Co-Founder & Board of Director

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

AB2 Bio Board Members (5)

Name Representing Role Since Contact
Info
Andrea Pfeifer Ph.D Self Chairwoman 000 0000
Barthélemy Helg AB2 Bio Co-Founder & Board of Director 000 0000
Bénédict Hentsch AB2 Bio Board Member 000 0000
Erich Hunziker Ph.D Self Board Member 000 0000
Gerald Cagle Ph.D AB2 Bio Board Member 000 0000